Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity

Victor H. Engelhard, Anthony B. Rodriguez, Ileana S. Mauldin, Amber N. Woods, J. David Peske and Craig L. Slingluff Jr.
J Immunol January 15, 2018, 200 (2) 432-442; DOI: https://doi.org/10.4049/jimmunol.1701269

Abstract

Limited representation of intratumoral immune cells is a major barrier to tumor control. However, simply enhancing immune responses in tumor-draining lymph nodes or through adoptive transfer may not overcome the limited ability of tumor vasculature to support effector infiltration. An alternative is to promote a sustained immune response intratumorally. This idea has gained traction with the observation that many tumors are associated with tertiary lymphoid structures (TLS), which organizationally resemble lymph nodes. These peri- and intratumoral structures are usually, but not always, associated with positive prognoses in patients. Preclinical and clinical data support a role for TLS in modulating immunity in the tumor microenvironment. However, there appear to be varied functions of TLS, potentially based on their structure or location in relation to the tumor or the origin or location of the tumor itself. Understanding more about TLS development, composition, and function may offer new therapeutic opportunities to modulate antitumor immunity.

Introduction

Substantial intratumoral representation of T lymphocytes, either spontaneously or after vaccination or adoptive therapy, is generally well correlated with immune-mediated control of human cancers (1–5). Importantly, the subset of patients who responds clinically to new-generation immunotherapies is those in whom an immunological infiltrate is evident prior to treatment (6–10). Thus, enhancing the representation of intratumoral immune effectors holds the promise of improving clinical outcomes. However, simply enhancing the immune response in the tumor-draining lymph node (LN) or by infusing large numbers of tumor-reactive T cells through adoptive transfer may not overcome the limitations of the tumor vasculature and microenvironment to support infiltration of these effectors. The desired approach would promote a sustained increase in functional intratumoral effector cells.

An interesting alternative is to promote development of an immune response inside the tumor, circumventing the limitations of dendritic cell (DC) trafficking from tumor to LN and of effector cells trafficking in the reverse direction. This idea originated in studies from the early 2000s, in which tumors were engineered to support naive T cell infiltration (11, 12). However, it has recently gained additional importance with the observation that many tumors are associated with tertiary lymphoid structures (TLS). TLS, which resemble LN, were initially described in conjunction with chronic and pathogen-driven immune responses. However, they are now recognized as a common feature in juxtaposition to tumors and are often associated with a positive prognosis in patients. In this article, we summarize the current state of knowledge about the significance of tumor-associated TLS. We place them in the context of immune infiltration into tumors more generally, as well as in the context of what is known about the development of conventional LN and inflammation-associated TLS. Finally, we point to the issues that still need to be addressed to harness them for therapeutic purposes.

Tumor-associated vasculature and control of T cell infiltration into tumors

Infiltration of tumors by exogenously activated effectors.

The entry of leukocytes, including T and B cells, into lymphoid and nonlymphoid tissues is controlled by sequential engagement of homing receptors (HR) (selectins, chemokine receptors, and integrins) that act with corresponding ligands on vascular endothelial cells to enable capture, rolling, firm adhesion, and extravasation (13–16). During differentiation, effector T cells acquire the ability to enter peripheral tissues, including tumors, by upregulating HR that bind to cognate ligands expressed on inflamed vasculature. HR expression on activated CD8 T cells is determined by the secondary lymphoid organ (SLO) in which priming occurs (17–21). Tissue-specific and inflammation-induced expression of different HR ligands, in conjunction with the patterns of HR expressed by T cells, determines which tissues are infiltrated.

Although the requirements for entry of effector T cells and other leukocytes into inflamed peripheral tissues, particularly skin and gut, have been well established, the requirements for entry into tumors remain inadequately defined. Several studies have unambiguously identified individual HR that mediate T cell infiltration into some tumors (22–27), whereas others have shown correlations between individual HR or HR ligands and T cell infiltrates (28–34). We recently completed a comprehensive analysis of the HR that mediate entry of CD8 T cell effectors into B16 melanoma and Lewis lung carcinoma and demonstrated that HR ligand expression on tumor-associated vasculature varies with anatomical location of the tumor (35). This also determines the ability of T cells activated in different SLO to enter tumors growing in different locations. Consistent with other work (25, 29, 32, 33, 36–41), we also found that HR ligand expression on tumor vasculature is often low. This is consistent with the low infiltration of adoptively transferred effector T cells observed in several studies (42–45). Thus, one opportunity to improve cancer immunotherapy is to identify and manipulate the expression of HR and HR ligands to enhance infiltration of CD8 T cell effectors into tumors. This approach has been explored by transducing adoptively transferred T cells to express various chemokine receptors and has resulted in enhanced infiltration and tumor control (46–49).

Naive T cells enter tumors through LN-like vasculature and enhance tumor control.

Naive T cells enter LN based on their expression of l-selectin and CCR7, which bind to peripheral node addressin (PNAd) and the chemokines CCL19/CCL21, respectively. The latter are expressed on specialized LN blood vessels called high endothelial venules (HEV). Because naive T cells do not generally enter peripheral tissue, it had been assumed that all intratumoral lymphocytes are effectors that differentiate in tumor-draining LN and home to the tumor thereafter. However, naive T cells were shown to infiltrate tumors that had been genetically modified to secrete lymphotoxin-α (LTα) (11, 50) or LIGHT (12). Tumors expressing LTα accumulated activated T cells in the absence of SLO (50). Similar results were obtained by intratumoral injection of CCL21 or CCL21-transduced DC (51–53). It was suggested that naive T cells infiltrated through a LN-like vasculature based on expression of CCL21 (12) or expression of CCL21 and PNAd and the accumulation of CD62L+ T cells (11), although this was not shown. In all of these models, the infiltration of naive T cells, in conjunction with their differentiation to become effectors, was shown to promote tumor destruction. These studies established that tumors could be engineered to serve as a surrogate site for naive T cell recruitment and their activation to become mediators of improved antitumor immunity.

More recently, we showed that adoptively transferred naive CD8 T cells can enter unmanipulated tumors and subsequently differentiate into functional effectors (54, 55). This also occurs in the absence of SLO (54). We also showed directly that naive CD8 T cell entry into tumors was entirely dependent on l-selectin and CCR7, as well as on the development of tumor-associated blood vessels that express PNAd and CCL21 (55). PNAd and CCL21 were coexpressed on ∼5% of blood vessels in tumors growing in multiple anatomical locations (55). The primary source of CCL21 was intratumoral gp38+ fibroblasts and, to a lesser extent, CD31+ blood endothelial cells. It was also shown that preventing this influx of naive T cells diminished tumor control, indicating that it represents an important component of the immune response in unmanipulated tumors.

Mechanisms driving PNAd and CCL21 expression on tumor-associated vasculature.

In adult LN, HEV morphology and expression of genes required for biosynthesis of PNAd are maintained by continuous engagement of lymphotoxin-α1β2 (LTα1β2) expressed on DC with the lymphotoxin-β receptor (LTβR) expressed on blood endothelial cells (56, 57). However, the genes for PNAd biosynthesis can also be induced in cultured endothelial cells and monocytes by TNF-α (58, 59). LTβR signaling does not control expression of CCL21 in adult LN (56). Developmentally, CCL21 expression can be induced by signals from LTα1β2; from soluble homotrimeric LTα3, which engages TNFR 1 and 2 (TNFR) but not LTβR (60–63); and from TNF-α (64, 65) and another TNFR family member, CD30 (66). However, it is not clear whether these signals regulate the expression of CCL21 directly or the development of CCL21-expressing cells. Overall, these results point to the central importance of LTα1β2–LTβR engagement in driving the development and maintenance of PNAd expression on blood endothelial cells, whereas control of CCL21 expression remains uncertain.

In tumors, the density of intratumoral DC (67) and regulatory T cell (Treg) depletion (68) was correlated with development of PNAd+ CCL21+ vasculature, but a cause and effect relationship was not established. Indeed, in murine models of melanoma and lung carcinoma, development of PNAd+ CCL21+ vasculature was not induced by DC or LTβR signaling (55). Instead, induction of both molecules depended on CD8 T cell effectors that had infiltrated tumors at an earlier point. In i.p. tumors, PNAd expression depended on CD8 T cell effectors secreting LTα3, which acted through TNFR expressed on endothelial cells and fibroblasts. CCL21, but not PNAd, also depended on IFN-γ secreted by CD8 T cell effectors, which acted through IFN-γ receptors on fibroblasts and endothelial cells. Control of PNAd and CCL21 in s.c. tumors was more complex, in that CD8 T cell effectors and NK cells could independently induce expression of these molecules. Although expression depends on signaling through TNFR, IFN-γ seems to act redundantly with another unidentified modulator to induce CCL21. These results demonstrate that the mechanisms controlling development of PNAd+ CCL21+ vasculature in tumors are distinct from those identified in SLO and also differ between s.c. and i.p. tumors. It remains to be determined whether these or additional mechanisms operate in human tumors growing in different anatomical locations.

TLS

TLS are lymphoid aggregates that frequently develop at sites of chronic infection, autoimmune disease, and allograft rejection (69–78). These structures have considerable morphological, cellular, and molecular similarity to SLO, particularly LN. Inflammation-associated TLS are associated with blood vascular endothelial cells that express PNAd and CCL21, similar to that of the tumors described above, and often have a characteristic “puffy” morphology. TLS contain B cells, T cells, and DC, which are typically organized into two distinct functional compartments: a B cell follicle primarily composed of naive B cells, surrounding a germinal center composed of highly proliferative B cells, and a T cell area mainly composed of T cells and DC (77, 79). In SLO, this microarchitecture is orchestrated by the homeostatic chemokines CCL19, CCL21, CXCL13, and CXCL12 (80–83). These chemokines are also found in TLS (84–88). Cells resembling fibroblastic reticular cells and follicular DC (FDC) have also been reported in well-developed TLS (63, 75, 84, 85, 87), suggesting that they may be the source of these chemokines and function as organizers of TLS. However, this remains to be demonstrated directly.

Identification and categorization of tumor-associated TLS.

Well-organized TLS have been described in association with several tumor types in humans, and two recent reviews have provided comprehensive summaries of this information (89, 90). The initial description in non–small cell lung cancers (91) documented large peritumoral aggregates of immune cells containing distinct T/DC and B/FDC zones, the latter of which also contained germinal centers. This group also documented the preferential expression of several homeostatic chemokines and HR ligands in these TLS (92), which correlated with the presence of larger numbers of CD4+ CD62L+ T cells (92, 93). Subsequent studies have largely replicated these findings in a number of tumor types in humans, although the range of cellular and molecular markers examined has been variable (67, 94–113). We (55) and other investigators (114, 115) have also identified TLS in murine tumors.

One significant consideration is how tumor-associated TLS are distinguished from otherwise localized immune cell infiltrates. In addition to the histological documentation of lymphoid aggregates, which are typically located peritumorally, most human studies have relied largely or exclusively on the presence of only some TLS-associated elements, including PNAd+ HEV (105, 106), mature DC (67, 91–93), B cells (99, 106), or follicular helper T (TFH) cells (102). A gene signature that includes CCL19, CCL21, and CXCL13, the homeostatic chemokines that likely organize TLS, also has been used (67, 96, 102, 106, 109, 111). Although it seems likely that the structures identified by all groups are indeed TLS, this points to the possibility of significant unappreciated heterogeneity in structure or composition that may arise in connection with different tumor types, anatomical locations, and primary or metastatic lesions.

In this regard, it was shown that colorectal metastases to the lung were associated with well-developed TLS in humans, whereas renal cell carcinoma metastases to the same organ were associated with poorly developed TLS (110). In human melanoma, it was found that TLS frequently developed in metastatic lesions yet were largely absent from primary tumors, despite the presence of a PNAd+ vasculature (95). Similarly, in the transplantable murine models that we have studied, TLS form around PNAd+ vasculature in all i.p. tumors, but not s.c. tumors, despite the presence of comparable LN-like vasculature (55, 116) (Fig. 1). The TLS found in these murine i.p. tumors also lack discrete B and T cell areas. Instead, T cells and DC are distributed within large B cell aggregates that, in turn, are organized within a reticular network of podoplanin+ fibroblasts (55, 116). In these i.p. tumor-associated TLS, it appears that the same podoplanin+ fibroblasts make CCL21 and CXCL13, which may explain the lack of discrete B and T cell areas. It remains to be determined how this difference in organization relative to more conventional SLO and TLS affects the nature of the immune response.

FIGURE 1.
FIGURE 1.

Intratumoral TLS with a nonclassical organization are found in association with PNAd+ vasculature in i.p. (B–D) but not s.c. (A) murine B16-OVA melanoma. Scale bars, 50 μm.

A second categorization of tumor-associated TLS is their anatomical relationship to the tumor mass. Almost all studies in humans have identified peritumoral TLS (summarized in Ref. 89), and TLS in this location have also been described in a genetically engineered mouse model (115). A smaller number of human studies have identified tumors with intratumoral TLS, usually as a subset of the tumors with peritumoral structures, although a largely intratumoral representation has also been reported in germ cell tumors (117; summarized in Ref. 89). The TLS in the transplantable murine models that we have used are exclusively intratumoral (55, 116). In studies of human melanoma metastases using seven-color immunofluorescence, we have identified TLS in 38% of metastatic melanomas (I.S. Mauldin and C.L. Slingluff, Jr., unpublished observations). They appear in three locations: stroma surrounding tumor nests (extratumoral), at the periphery of the tumor nests (peritumoral), and intratumoral. In general, TLS are more organized with discrete B cell and DC/T cell zones in peritumoral and extratumoral locations (Fig. 2A–D) than within the tumor nests (Fig. 2E, 2F). However, some peritumoral TLS also show an intermixing of T cells within B cell aggregates (Fig. 2C). FOXP3+ putative Treg are prevalent in the T cell area. We have also detected intratumoral PNAd+ vasculature that is not associated with well-organized aggregates, although there are diffuse distributions of lymphocytes and DC in the general vicinity (Fig. 2F). An important set of questions is whether these levels of TLS organization in different locations are formed by distinct mechanisms, have distinct immunological properties, or have distinct prognostic values in relation to patient survival and response to immunotherapy.

FIGURE 2.
FIGURE 2.

Multispectral imaging of TLS in human melanoma metastases localized outside the tumor area (A), peritumorally at the peripheral edge of tumor (B–D), or intratumorally (E and F). Artifactual tissue creases due to sectioning can be seen in (B) and (C). Scale bars, 100 μm.

Prognostic significance and immunological impact of tumor-associated TLS.

TLS are often found in lungs in response to acute infection (77, 78) where they lead to enhanced local antiviral immunity through activation of naive T cells (71, 72). In keeping with this, tumor-associated TLS are usually a favorable prognostic indicator for patient survival (reviewed in Refs. 89, 90), although there are exceptions (110, 118). Several studies have pointed to the relationship among the densities of HEV, CD4 or TFH cells, B cells, and mature DC in defining TLS, as well as to a relationship among the densities of TLS, levels of intratumoral T and B cells, and a TH1/cytotoxic immune profile among tumor infiltrating lymphocytes (TIL) (92, 93, 96, 97, 99, 112, 119). These observations are most often interpreted to mean that tumor-associated TLS are sites for generating useful antitumor immune responses in newly entering naive T and B cells.

An alternative possibility is that TLS are simply proxies for more robust intratumoral CD8 T cell effector activity. Because intratumoral CD8 T cells have been implicated most often as positive prognostic factors for cancer patient survival, the prognostic value of TLS needs to be evaluated through multivariate analysis capable of distinguishing independent effects. One recent study concluded that TLS did have independent value after controlling for specific TIL variables (97). Another study established that a subset of individuals with low TLS-associated DC density were at great risk for death, despite the presence of a high density of CD8 effectors (93). Interestingly, the presence of TLS in triple-negative breast cancer added to the positive prognostic value of moderate levels of TIL, but it had no impact if there were high levels of TIL present (105). At the other extreme, TLS had positive prognostic value in Merkel cell carcinoma, whereas T cell infiltration and several other immunological parameters did not (119). Similarly, neither CD8 nor TH17 TIL was associated with a positive prognosis in gastric cancer patients; however, Tbet+ cells, CD20 B cells organized into TLS, and coordinate expression of TH1 and B cell genes were associated with a positive prognosis (103). Curiously, however, DC–Lamp+ cell density, another TLS marker, did not have prognostic value.

Conversely, a limited number of studies have shown that tumor-associated TLS are a negative prognostic factor for cancer patient survival. The presence of TLS in colorectal cancer has been associated with more advanced disease (118), whereas TLS in breast cancer was associated with a higher tumor grade, low representation of intratumoral immune cells, and a high frequency of LN metastasis (120). These studies are seemingly at odds with studies suggesting positive associations with patient survival in each of these diseases (67, 97, 102, 105–107, 110, 112) and remain to be fully reconciled. An intriguing study showed a negative impact of DC-Lamp and CD8 markers on survival of patients with renal cell carcinoma metastases to lung but a positive impact on patients with colorectal cancer metastases to the same organ (110). In murine lung adenocarcinoma, it was shown that TLS serve as a site for recruitment of Treg that restrain antitumor immune responses (115). It was also shown that TLS can function as niches for malignant hepatocellular progenitor cells (98). Interestingly, in human lung transplants, TLS have been associated with a lower probability of graft rejection, whereas some other organ transplants are more likely to be rejected when TLS are identified (121–123). Thus, in cancers and in transplanted organs, immune rejection may be enhanced or reduced by the presence of TLS. This raises the possibility that some TLS are dominated by Treg and support tolerance, whereas others support immune rejection. It will be important to understand details of the composition and location of TLS and which is more relevant for immune rejection.

A characteristic feature of all tumor-associated TLS in humans and mice is the presence of a large number of B lymphocytes, often accompanied by TFH cells. In recent years, the consensus of the field has become that CD8 T cells are the most important determinant of antitumor immunity; however, these observations suggest that intratumoral B cells may play an important role(s). On the positive side, several studies have suggested that intratumoral B cells can capture and present tumor Ags to T cells (124–126). Perhaps even more heretical (in the current environment) have been suggestions that intratumoral Ab responses can be an effective component of antitumor immunity (127, 128). On the negative side, many studies have shown that B cells can play a suppressive role in antitumor immunity, and regulatory B cells have been found to accumulate in several tumor models (129–132). The differences in prognostic significance of tumor-associated TLS may lie, at least in part, in the distinct functional attributes of the B cell compartment in different tumors. However, the ways in which tumors may regulate these functional attributes remain to be discovered.

Collectively, these studies point to a complex interplay in which the prognostic value of TIL and TLS depends at the very least on tumor type. It seems likely that different tumor types may drive qualitatively distinct immune responses, distinguishable by their effector and regulatory mechanisms. Such responses may also evolve over time. In some tumors, or at certain times, these may be determined largely within conventional tumor-draining SLO, whereas in other circumstances, they may be determined within tumor-associated TLS. Evidence demonstrating such a temporal evolution has recently been reported (94). This suggests that TLS “quality” might also confer, or result from, distinct kinds of immunity or immune regulation. Genetically engineered mouse models (115) provide a valuable opportunity to evaluate these variables systematically.

Mechanisms that control the development of TLS.

The development of conventional LN depends on interaction between CD4+ CD3neg lymphoid tissue inducer (LTi) cells expressing LTα1β2 and RANKL [now known to be group 3 innate lymphoid cells (133)] and mesenchymal lymphoid tissue organizer cells expressing LTβR (134–139). This leads to expression of CCL19, CCL21, and CXCL13, which attract additional LTi cells, and the recruitment and positioning of T and B cells (81, 140–142). In keeping with this, mice deficient in LTα, LTβ, or LTβR fail to develop all or most LN (143–146). The formation of FDC networks and germinal centers as an element of LN development depends on engagement of TNFR, as well as LTβR (147). LTβR signaling does not control expression of CCL21 in adult LN (56), although it does maintain CXCL13 expression in adult spleen (148), presumably through interaction of LTα1β2-expressing B cells with LTβR+ FDC (149, 150).

A key question is whether the formation of TLS in general, and tumor-associated TLS in particular, occurs through pathways analogous to those controlling conventional LN development. Transgenic expression of LTα or LTβ in various organs leads to the formation of organized lymphoid aggregates typically identified as TLS, although they are not driven by an immune response (60–63). Transgenic expression of CCL21 also leads to formation of such structures, although PNAd expression still depends on LTβR signaling (151, 152), and this operates through mature CD4 T cells rather than LTi cells (153). Importantly, blockade of LTβR signaling prevents immune response–driven TLS formation in thyroid, lung, salivary gland, aorta, and heart (71, 88, 154–157). These studies suggest that development of LN and TLS is mechanistically similar.

In contrast, TLS have been shown to depend on TNF-α in aorta, fat, and intestine (158–160), IL-22 in salivary gland (84), and IL-17A in lung and meninges (86, 88, 161). IL-6 and IL-23 also contribute to TLS development through IL-17A–dependent and -independent pathways (162–164). Although the exact mechanisms of action remain to be fully defined, TNF-α induces CCL21 (64, 65), CXCL13 (148), and enzymes necessary for PNAd synthesis (58, 59), whereas IL-22 and IL-17A induce CXCL12 and CXCL13 in TLS-associated stromal cells (84, 85, 88, 165, 166). These cytokines sometimes induce TLS independent of LTβR signaling (158, 160), but in other instances they act cooperatively, either by inducing distinct aspects of TLS structure (84, 86) or by acting at the TLS-induction or maintenance phases (88). Importantly, different pathogens can induce lung-associated TLS by distinct cellular and molecular pathways (85). The involvement of additional cytokines in the formation and/or maintenance of many LTβR-dependent TLS remains to be evaluated.

Aside from the involvement of distinct molecular signaling pathways in TLS formation, a variety of inducing cells, in lieu of LTi cells, have been identified. This includes DC (71, 72, 167) and naive B cells (168), both expressing LTα1β2; macrophages (158–160), TH17 cells (86, 88, 161), NKT cells (158), γδ T cells (85), and multiple populations of IL-22–secreting adaptive and innate lymphoid cells (84). Overall, it should be expected that distinct molecular signals, conveyed by immune cells with pleiotropic regulatory signatures, will induce TLS with important differences in the immune responses that they support.

In this context, the mechanisms driving TLS formation in tumors remain almost entirely unknown. Analogous to the overexpression models described above, transgenic expression of LTα or LIGHT in tumors (11, 169) or intratumoral administration of CCL21 (52, 53) establishes that these pathways can lead to TLS formation. In transplantable murine tumors, TLS develop in i.p., but not in s.c., tumors (55, 116), suggesting that the mechanisms controlling their development depend on anatomical environmental factors and providing an opportunity to gain insight into these mechanisms through comparative analysis. Because PNAd+ CCL21+ vasculature develops comparably in tumors growing in both locations, this also points to distinct mechanisms controlling these two features, as well as to this vasculature in providing a nucleation site for TLS formation.

Compared with s.c. tumors, i.p. tumors showed a 10-fold increase in the number of B cells relative to CD31+ vascular endothelial cells, whereas the numbers of T cells and DC were similar (116). Interestingly, i.p. tumors also showed a 5-fold relative increase in podoplanin+ fibroblasts, and these cells formed a reticular network surrounding the PNAd+ CCL21+ vasculature, which was coextensive with the B cells (55, 116). Although perivascular podoplanin+ cells were evident in s.c. tumors, they had not expanded to form reticular networks. Also, podoplanin+ cells in i.p. tumors expressed significantly higher levels of CXCL13 and the B cell survival factors BAFF and APRIL (A.B. Rodriguez, J.D. Peske, S. Cyranowski, G. Parriott, and V.H. Engelhard, manuscript in preparation), which are important for the development and survival of B cells (170–172) and maintaining the integrity of germinal centers (173, 174). This suggests that elements of the i.p. tumor microenvironment induce proliferation and differentiation of podoplanin+ cells, which act as scaffolding for TLS formation. Although our work establishes that CCL21 recruits naive T cells into i.p. and s.c. tumors (55), it remains to be directly determined whether and how these remaining molecules impact B cell recruitment and the formation of TLS in i.p. tumors and what mechanism is responsible for changes in their expression in tumor-associated podoplanin+ fibroblasts (Fig. 3).

FIGURE 3.
FIGURE 3.

Model for the formation of nonclassical and classical tumor-associated TLS.

Conclusions

Tumor-associated TLS have been frequently correlated with improved patient survival and in murine models have generally been associated with the development of improved immune-mediated tumor control. However, tumor-associated TLS have also been identified as a locus of Treg accumulation, and they characteristically contain large numbers of B cells, which exert a regulatory role in several tumor models. Much remains to be done to fully understand the immune mechanisms that are activated within these structures and whether these vary based on the origin of the tumor, the oncogenic drivers leading to its formation, or its anatomical location as a primary tumor or metastatic lesion. To do so will require application of the full range of technologies that have been applied in previous studies, together with a more comprehensive analysis of molecules that mark various immune mechanisms. Advances in multispectral imaging of single sections, and entire tumors after tissue clearing, and advances in small-scale RNA sequencing combined with laser capture dissection of TLS create new opportunities for comprehensive assessment of cellular composition and functional state of individual TLS in a variety of contexts. This work is also important as a means to more clearly establish the prognostic value of TLS, independent of other immune factors.

The pathways that drive the formation of PNAD+ CCL21+ vasculature have been uncovered in a limited number of murine tumor models, but the factors that drive formation and/or maintenance of tumor-associated TLS remain almost completely unknown. Studies in a variety of inflammation-driven TLS models have pointed to a number of molecular and cellular mediators that work in collaboration with or in lieu of more classical mechanisms that underlie the formation of SLO. This heterogeneity has been shown to reflect, at least in part, the nature of the inflammatory stimulus. One might also imagine a role for anatomical location, reflecting the extent to which peripheral tissues are invested with different subsets of myeloid derived cells, innate lymphoid cells, or tissue-resident memory cells. The impact of the pre-existing or early-stage microenvironment in proximity to tumors on TLS formation is clear, but the exact drivers and how they vary based on tumor origin or location remain to be determined. These drivers are likely to also influence the composition and function of TLS, as mentioned above. Understanding these driver mechanisms will rely heavily on appropriate transplantable and genetically induced mouse models, in which they can be directly tested through knockout or blockade approaches. Their validity in human settings will be more difficult to establish, because it will depend largely on correlative studies to establish the presence or absence of various cells or signaling molecules. However, as argued above, incisive multiparameter correlative studies are key to understanding the prognostic significance of TLS in humans. Together with work in mouse models, they will provide the basis for moving forward to manipulate TLS incidence, location, composition, and function.

Based on the preponderance of evidence, it seems highly desirable, in most settings, to increase the number of TLS as a way to promote an ongoing immune response in immediate proximity to tumor cells, avoiding the need for two-way cellular traffic between tumor and tumor-draining SLO. One open question is whether this is best achieved via intratumoral or peritumoral TLS. Related to this is the question of whether regulatory mechanisms that often occur within the tumor microenvironment are more prevalent within, or in proximity to, TLS. A second set of questions concerns TLS functionality. It remains to be established how TLS and tumor-draining SLO compare as sites for development of tumor-specific CD8 T cells, either numerically or over time. The presence of large numbers of B cells in TLS has brought renewed focus on the positive and negative roles that B cells might play in antitumor immunity, but this has yet to be clearly tied to the activity of B cells within TLS. Finally, but more immediately in the current clinical environment, there are open questions about whether the presence of TLS, either pre- or posttreatment, has prognostic value in responses to checkpoint blockade therapy. Does checkpoint blockade enhance TLS formation or enhance TLS function as a site for de novo antitumor immune responses? As new immune therapeutic modalities (e.g., IDO inhibitors, myeloid cell depletion) come into the clinical landscape, these questions will only get broader.

Overall, the work accomplished to date clearly establishes the importance of tumor-associated TLS as an aspect of immunological control of tumors. However, a substantial amount of work remains to be done to fully understand how they are important, as well as how to begin to use them as an element of our developing armamentarium of immunological cancer control strategies.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • This work was supported by United States Public Health Service Grants CA78400 and CA181794 (to V.H.E.) and Training Grants GM007267 (to J.D.P.) and AI007496 (to A.B.R. and A.N.W.). J.D.P. was the recipient of a Farrow Fellowship, and A.B.R. was the recipient of a Wagner Fellowship.

  • Abbreviations used in this article:

    DC
    dendritic cell
    FDC
    follicular DC
    HEV
    high endothelial venule
    HR
    homing receptor
    LN
    lymph node
    LTα
    lymphotoxin-α
    LTα1β2
    lymphotoxin-α1β2
    LTi
    lymphoid tissue inducer
    LTβR
    lymphotoxin-β receptor
    PNAd
    peripheral node addressin
    SLO
    secondary lymphoid organ
    TFH
    follicular helper T
    TIL
    tumor infiltrating lymphocyte
    TLS
    tertiary lymphoid structure
    Treg
    regulatory T cell.

  • Received September 6, 2017.
  • Accepted October 19, 2017.

References

  1. ↵
    1. Pagès, F.,
    2. A. Berger,
    3. M. Camus,
    4. F. Sanchez-Cabo,
    5. A. Costes,
    6. R. Molidor,
    7. B. Mlecnik,
    8. A. Kirilovsky,
    9. M. Nilsson,
    10. D. Damotte, et al
    . 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353: 2654–2666.
    OpenUrlCrossRefPubMed
    1. Galon, J.,
    2. A. Costes,
    3. F. Sanchez-Cabo,
    4. A. Kirilovsky,
    5. B. Mlecnik,
    6. C. Lagorce-Pagès,
    7. M. Tosolini,
    8. M. Camus,
    9. A. Berger,
    10. P. Wind, et al
    . 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960–1964.
    OpenUrlAbstract/FREE Full Text
    1. Sato, E.,
    2. S. H. Olson,
    3. J. Ahn,
    4. B. Bundy,
    5. H. Nishikawa,
    6. F. Qian,
    7. A. A. Jungbluth,
    8. D. Frosina,
    9. S. Gnjatic,
    10. C. Ambrosone, et al
    . 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 102: 18538–18543.
    OpenUrlAbstract/FREE Full Text
    1. Erdag, G.,
    2. J. T. Schaefer,
    3. M. E. Smolkin,
    4. D. H. Deacon,
    5. S. M. Shea,
    6. L. T. Dengel,
    7. J. W. Patterson,
    8. C. L. Slingluff Jr..
    2012. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res. 72: 1070–1080.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Angell, H.,
    2. J. Galon
    . 2013. From the immune contexture to the immunoscore: the role of prognostic and predictive immune markers in cancer. Curr. Opin. Immunol. 25: 261–267.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Gajewski, T. F.,
    2. J. Louahed,
    3. V. G. Brichard
    . 2010. Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy. Cancer J. 16: 399–403.
    OpenUrlCrossRefPubMed
    1. Ulloa-Montoya, F.,
    2. J. Louahed,
    3. B. Dizier,
    4. O. Gruselle,
    5. B. Spiessens,
    6. F. F. Lehmann,
    7. S. Suciu,
    8. W. H. Kruit,
    9. A. M. Eggermont,
    10. J. Vansteenkiste,
    11. V. G. Brichard
    . 2013. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J. Clin. Oncol. 31: 2388–2395.
    OpenUrlAbstract/FREE Full Text
    1. Ji, R.-R.,
    2. S. D. Chasalow,
    3. L. Wang,
    4. O. Hamid,
    5. H. Schmidt,
    6. J. Cogswell,
    7. S. Alaparthy,
    8. D. Berman,
    9. M. Jure-Kunkel,
    10. N. O. Siemers, et al
    . 2012. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol. Immunother. 61: 1019–1031.
    OpenUrlCrossRefPubMed
    1. Herbst, R. S.,
    2. J.-C. Soria,
    3. M. Kowanetz,
    4. G. D. Fine,
    5. O. Hamid,
    6. M. S. Gordon,
    7. J. A. Sosman,
    8. D. F. McDermott,
    9. J. D. Powderly,
    10. S. N. Gettinger, et al
    . 2014. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515: 563–567.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Gajewski, T. F.,
    2. H. Schreiber,
    3. Y.-X. Fu
    . 2013. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14: 1014–1022.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Schrama, D.,
    2. P. thor Straten,
    3. W. H. Fischer,
    4. A. D. McLellan,
    5. E. B. Bröcker,
    6. R. A. Reisfeld,
    7. J. C. Becker
    . 2001. Targeting of lymphotoxin-α to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity 14: 111–121.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Yu, P.,
    2. Y. Lee,
    3. W. Liu,
    4. R. K. Chin,
    5. J. Wang,
    6. Y. Wang,
    7. A. Schietinger,
    8. M. Philip,
    9. H. Schreiber,
    10. Y. X. Fu
    . 2004. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat. Immunol. 5: 141–149.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Butcher, E. C.,
    2. L. J. Picker
    . 1996. Lymphocyte homing and homeostasis. Science 272: 60–66.
    OpenUrlAbstract
    1. von Andrian, U. H.,
    2. C. R. Mackay
    . 2000. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343: 1020–1034.
    OpenUrlCrossRefPubMed
    1. Sackstein, R.
    2005. The lymphocyte homing receptors: gatekeepers of the multistep paradigm. Curr. Opin. Hematol. 12: 444–450.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Ley, K.,
    2. C. Laudanna,
    3. M. I. Cybulsky,
    4. S. Nourshargh
    . 2007. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7: 678–689.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Mora, J. R.,
    2. M. R. Bono,
    3. N. Manjunath,
    4. W. Weninger,
    5. L. L. Cavanagh,
    6. M. Rosemblatt,
    7. U. H. Von Andrian
    . 2003. Selective imprinting of gut-homing T cells by Peyer’s patch dendritic cells. Nature 424: 88–93.
    OpenUrlCrossRefPubMed
    1. Mora, J. R.,
    2. G. Cheng,
    3. D. Picarella,
    4. M. Briskin,
    5. N. Buchanan,
    6. U. H. von Andrian
    . 2005. Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J. Exp. Med. 201: 303–316.
    OpenUrlAbstract/FREE Full Text
    1. Johansson-Lindbom, B.,
    2. W. W. Agace
    . 2007. Generation of gut-homing T cells and their localization to the small intestinal mucosa. Immunol. Rev. 215: 226–242.
    OpenUrlCrossRefPubMed
    1. Sigmundsdottir, H.,
    2. E. C. Butcher
    . 2008. Environmental cues, dendritic cells and the programming of tissue-selective lymphocyte trafficking. Nat. Immunol. 9: 981–987.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Ferguson, A. R.,
    2. V. H. Engelhard
    . 2010. CD8 T cells activated in distinct lymphoid organs differentially express adhesion proteins and coexpress multiple chemokine receptors. J. Immunol. 184: 4079–4086.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Yamada, M.,
    2. K. Yanaba,
    3. M. Hasegawa,
    4. Y. Matsushita,
    5. M. Horikawa,
    6. K. Komura,
    7. T. Matsushita,
    8. A. Kawasuji,
    9. T. Fujita,
    10. K. Takehara, et al
    . 2006. Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. Clin. Exp. Immunol. 143: 216–227.
    OpenUrlCrossRefPubMed
    1. Sasaki, K.,
    2. X. Zhu,
    3. C. Vasquez,
    4. F. Nishimura,
    5. J. E. Dusak,
    6. J. Huang,
    7. M. Fujita,
    8. A. Wesa,
    9. D. M. Potter,
    10. P. R. Walker, et al
    . 2007. Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors. Cancer Res. 67: 6451–6458.
    OpenUrlAbstract/FREE Full Text
    1. Buckanovich, R. J.,
    2. A. Facciabene,
    3. S. Kim,
    4. F. Benencia,
    5. D. Sasaroli,
    6. K. Balint,
    7. D. Katsaros,
    8. A. O’Brien-Jenkins,
    9. P. A. Gimotty,
    10. G. Coukos
    . 2008. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14: 28–36.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Fisher, D. T.,
    2. Q. Chen,
    3. J. J. Skitzki,
    4. J. B. Muhitch,
    5. L. Zhou,
    6. M. M. Appenheimer,
    7. T. D. Vardam,
    8. E. L. Weis,
    9. J. Passanese,
    10. W.-C. Wang, et al
    . 2011. IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J. Clin. Invest. 121: 3846–3859.
    OpenUrlCrossRefPubMed
    1. Bose, A.,
    2. J. L. Taylor,
    3. S. Alber,
    4. S. C. Watkins,
    5. J. A. Garcia,
    6. B. I. Rini,
    7. J. S. Ko,
    8. P. A. Cohen,
    9. J. H. Finke,
    10. W. J. Storkus
    . 2011. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int. J. Cancer 129: 2158–2170.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Mikucki, M. E.,
    2. D. T. Fisher,
    3. J. Matsuzaki,
    4. J. J. Skitzki,
    5. N. B. Gaulin,
    6. J. B. Muhitch,
    7. A. W. Ku,
    8. J. G. Frelinger,
    9. K. Odunsi,
    10. T. F. Gajewski, et al
    . 2015. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun. 6: 7458.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Kunz, M.,
    2. A. Toksoy,
    3. M. Goebeler,
    4. E. Engelhardt,
    5. E. Bröcker,
    6. R. Gillitzer
    . 1999. Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J. Pathol. 189: 552–558.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Garbi, N.,
    2. B. Arnold,
    3. S. Gordon,
    4. G. J. Hämmerling,
    5. R. Ganss
    . 2004. CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J. Immunol. 172: 5861–5869.
    OpenUrlAbstract/FREE Full Text
    1. Hensbergen, P. J.,
    2. P. G. Wijnands,
    3. M. W. Schreurs,
    4. R. J. Scheper,
    5. R. Willemze,
    6. C. P. Tensen
    . 2005. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. J. Immunother. 28: 343–351.
    OpenUrlCrossRef
    1. Musha, H.,
    2. H. Ohtani,
    3. T. Mizoi,
    4. M. Kinouchi,
    5. T. Nakayama,
    6. K. Shiiba,
    7. K. Miyagawa,
    8. H. Nagura,
    9. O. Yoshie,
    10. I. Sasaki
    . 2005. Selective infiltration of CCR5+CXCR3+ T lymphocytes in human colorectal carcinoma. Int. J. Cancer 116: 949–956.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Clark, R. A.,
    2. S. J. Huang,
    3. G. F. Murphy,
    4. I. G. Mollet,
    5. D. Hijnen,
    6. M. Muthukuru,
    7. C. F. Schanbacher,
    8. V. Edwards,
    9. D. M. Miller,
    10. J. E. Kim, et al
    . 2008. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J. Exp. Med. 205: 2221–2234.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Quezada, S. A.,
    2. K. S. Peggs,
    3. T. R. Simpson,
    4. Y. Shen,
    5. D. R. Littman,
    6. J. P. Allison
    . 2008. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205: 2125–2138.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Lohr, J.,
    2. T. Ratliff,
    3. A. Huppertz,
    4. Y. Ge,
    5. C. Dictus,
    6. R. Ahmadi,
    7. S. Grau,
    8. N. Hiraoka,
    9. V. Eckstein,
    10. R. C. Ecker, et al
    . 2011. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin. Cancer Res. 17: 4296–4308.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Woods, A. N.,
    2. A. L. Wilson,
    3. N. Srinivasan,
    4. J. Zeng,
    5. A. Dutta,
    6. J. D. Peske,
    7. E. F. Tewalt,
    8. R. K. Gregg,
    9. A. R. Ferguson,
    10. V. H. Engelhard
    . 2017. Anatomical location and effector cytokines determine homing receptor ligand expression on tumor-associated vasculature and the entry of effector CD8 T-cells. Cancer Immunol. Res. DOI: 10.1158/2326-6066.CIR-17-0190.
  36. ↵
    1. Weishaupt, C.,
    2. K. N. Munoz,
    3. E. Buzney,
    4. T. S. Kupper,
    5. R. C. Fuhlbrigge
    . 2007. T-cell distribution and adhesion receptor expression in metastatic melanoma. Clin. Cancer Res. 13: 2549–2556.
    OpenUrlAbstract/FREE Full Text
    1. Dengel, L. T.,
    2. A. G. Norrod,
    3. B. L. Gregory,
    4. E. Clancy-Thompson,
    5. M. D. Burdick,
    6. R. M. Strieter,
    7. C. L. Slingluff Jr..,
    8. D. W. Mullins
    . 2010. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J. Immunother. 33: 965–974.
    OpenUrlCrossRef
    1. Enarsson, K.,
    2. E. Johnsson,
    3. C. Lindholm,
    4. A. Lundgren,
    5. Q. Pan-Hammarström,
    6. E. Strömberg,
    7. P. Bergin,
    8. E.-L. Baunge,
    9. A.-M. Svennerholm,
    10. M. Quiding-Järbrink
    . 2006. Differential mechanisms for T lymphocyte recruitment in normal and neoplastic human gastric mucosa. Clin. Immunol. 118: 24–34.
    OpenUrlPubMed
    1. Dirkx, A. E. M.,
    2. M. G. A. oude Egbrink,
    3. M. J. E. Kuijpers,
    4. S. T. van der Niet,
    5. V. V. T. Heijnen,
    6. J. C. A. Bouma-ter Steege,
    7. J. Wagstaff,
    8. A. W. Griffioen
    . 2003. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res. 63: 2322–2329.
    OpenUrlAbstract/FREE Full Text
    1. Yoong, K. F.,
    2. G. McNab,
    3. S. G. Hübscher,
    4. D. H. Adams
    . 1998. Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J. Immunol. 160: 3978–3988.
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. Harlin, H.,
    2. Y. Meng,
    3. A. C. Peterson,
    4. Y. Zha,
    5. M. Tretiakova,
    6. C. Slingluff,
    7. M. McKee,
    8. T. F. Gajewski
    . 2009. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69: 3077–3085.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Griffith, K. D.,
    2. E. J. Read,
    3. J. A. Carrasquillo,
    4. C. S. Carter,
    5. J. C. Yang,
    6. B. Fisher,
    7. P. Aebersold,
    8. B. S. Packard,
    9. M. Y. Yu,
    10. S. A. Rosenberg
    . 1989. In vivo distribution of adoptively transferred indium-111-labeled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J. Natl. Cancer Inst. 81: 1709–1717.
    OpenUrlCrossRefPubMed
    1. Fisher, B.,
    2. B. S. Packard,
    3. E. J. Read,
    4. J. A. Carrasquillo,
    5. C. S. Carter,
    6. S. L. Topalian,
    7. J. C. Yang,
    8. P. Yolles,
    9. S. M. Larson,
    10. S. A. Rosenberg
    . 1989. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7: 250–261.
    OpenUrlAbstract
    1. Economou, J. S.,
    2. A. S. Belldegrun,
    3. J. Glaspy,
    4. E. M. Toloza,
    5. R. Figlin,
    6. J. Hobbs,
    7. N. Meldon,
    8. R. Kaboo,
    9. C. L. Tso,
    10. A. Miller, et al
    . 1996. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial. J. Clin. Invest. 97: 515–521.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Kershaw, M. H.,
    2. J. A. Westwood,
    3. L. L. Parker,
    4. G. Wang,
    5. Z. Eshhar,
    6. S. A. Mavroukakis,
    7. D. E. White,
    8. J. R. Wunderlich,
    9. S. Canevari,
    10. L. Rogers-Freezer, et al
    . 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106–6115.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Craddock, J. A.,
    2. A. Lu,
    3. A. Bear,
    4. M. Pule,
    5. M. K. Brenner,
    6. C. M. Rooney,
    7. A. E. Foster
    . 2010. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33: 780–788.
    OpenUrlCrossRefPubMed
    1. Di Stasi, A.,
    2. B. De Angelis,
    3. C. M. Rooney,
    4. L. Zhang,
    5. A. Mahendravada,
    6. A. E. Foster,
    7. H. E. Heslop,
    8. M. K. Brenner,
    9. G. Dotti,
    10. B. Savoldo
    . 2009. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 113: 6392–6402.
    OpenUrlAbstract/FREE Full Text
    1. Peng, W.,
    2. Y. Ye,
    3. B. A. Rabinovich,
    4. C. Liu,
    5. Y. Lou,
    6. M. Zhang,
    7. M. Whittington,
    8. Y. Yang,
    9. W. W. Overwijk,
    10. G. Lizée,
    11. P. Hwu
    . 2010. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16: 5458–5468.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Moon, E. K.,
    2. C. Carpenito,
    3. J. Sun,
    4. L.-C. S. Wang,
    5. V. Kapoor,
    6. J. Predina,
    7. D. J. Powell Jr..,
    8. J. L. Riley,
    9. C. H. June,
    10. S. M. Albelda
    . 2011. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17: 4719–4730.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Schrama, D.,
    2. H. Voigt,
    3. A. O. Eggert,
    4. R. Xiang,
    5. H. Zhou,
    6. T. N. M. Schumacher,
    7. M. H. Andersen,
    8. P. thor Straten,
    9. R. A. Reisfeld,
    10. J. C. Becker
    . 2008. Immunological tumor destruction in a murine melanoma model by targeted LTalpha independent of secondary lymphoid tissue. Cancer Immunol. Immunother. 57: 85–95.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Kirk, C. J.,
    2. D. Hartigan-O’Connor,
    3. B. J. Nickoloff,
    4. J. S. Chamberlain,
    5. M. Giedlin,
    6. L. Aukerman,
    7. J. J. Mulé
    . 2001. T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy. Cancer Res. 61: 2062–2070.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Kirk, C. J.,
    2. D. Hartigan-O’Connor,
    3. J. J. Mulé
    . 2001. The dynamics of the T-cell antitumor response: chemokine-secreting dendritic cells can prime tumor-reactive T cells extranodally. Cancer Res. 61: 8794–8802.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Turnquist, H. R.,
    2. X. Lin,
    3. A. E. Ashour,
    4. M. A. Hollingsworth,
    5. R. K. Singh,
    6. J. E. Talmadge,
    7. J. C. Solheim
    . 2007. CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. Int. J. Oncol. 30: 631–639.
    OpenUrlPubMed
  54. ↵
    1. Thompson, E. D.,
    2. H. L. Enriquez,
    3. Y.-X. Fu,
    4. V. H. Engelhard
    . 2010. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors. J. Exp. Med. 207: 1791–1804.
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Peske, J. D.,
    2. E. D. Thompson,
    3. L. Gemta,
    4. R. A. Baylis,
    5. Y.-X. Fu,
    6. V. H. Engelhard
    . 2015. Effector lymphocyte-induced lymph node-like vasculature enables naive T-cell entry into tumours and enhanced anti-tumour immunity. Nat. Commun. 6: 7114.
    OpenUrlCrossRefPubMed
  56. ↵
    1. Browning, J. L.,
    2. N. Allaire,
    3. A. Ngam-Ek,
    4. E. Notidis,
    5. J. Hunt,
    6. S. Perrin,
    7. R. A. Fava
    . 2005. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 23: 539–550.
    OpenUrlCrossRefPubMed
  57. ↵
    1. Moussion, C.,
    2. J.-P. Girard
    . 2011. Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature 479: 542–546.
    OpenUrlCrossRefPubMed
  58. ↵
    1. Pablos, J. L.,
    2. B. Santiago,
    3. D. Tsay,
    4. M. S. Singer,
    5. G. Palao,
    6. M. Galindo,
    7. S. D. Rosen
    . 2005. A HEV-restricted sulfotransferase is expressed in rheumatoid arthritis synovium and is induced by lymphotoxin-α/β and TNF-α in cultured endothelial cells. BMC Immunol. 6: 6.
    OpenUrlCrossRefPubMed
  59. ↵
    1. Tjew, S. L.,
    2. K. L. Brown,
    3. R. Kannagi,
    4. P. Johnson
    . 2005. Expression of N-acetylglucosamine 6-O-sulfotransferases (GlcNAc6STs)-1 and -4 in human monocytes: GlcNAc6ST-1 is implicated in the generation of the 6-sulfo N-acetyllactosamine/Lewis x epitope on CD44 and is induced by TNF-α. Glycobiology 15: 7C–13C.
    OpenUrlCrossRefPubMed
  60. ↵
    1. Sacca, R.,
    2. C. A. Cuff,
    3. W. Lesslauer,
    4. N. H. Ruddle
    . 1998. Differential activities of secreted lymphotoxin-α3 and membrane lymphotoxin-α1β2 in lymphotoxin-induced inflammation: critical role of TNF receptor 1 signaling. J. Immunol. 160: 485–491.
    OpenUrlAbstract/FREE Full Text
    1. Cuff, C. A.,
    2. J. Schwartz,
    3. C. M. Bergman,
    4. K. S. Russell,
    5. J. R. Bender,
    6. N. H. Ruddle
    . 1998. Lymphotoxin α3 induces chemokines and adhesion molecules: insight into the role of LT α in inflammation and lymphoid organ development. J. Immunol. 161: 6853–6860.
    OpenUrlAbstract/FREE Full Text
    1. Cuff, C. A.,
    2. R. Sacca,
    3. N. H. Ruddle
    . 1999. Differential induction of adhesion molecule and chemokine expression by LTalpha3 and LTalphabeta in inflammation elucidates potential mechanisms of mesenteric and peripheral lymph node development. J. Immunol. 162: 5965–5972.
    OpenUrlAbstract/FREE Full Text
  63. ↵
    1. Drayton, D. L.,
    2. X. Ying,
    3. J. Lee,
    4. W. Lesslauer,
    5. N. H. Ruddle
    . 2003. Ectopic LT α β directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. J. Exp. Med. 197: 1153–1163.
    OpenUrlAbstract/FREE Full Text
  64. ↵
    1. Johnson, L. A.,
    2. D. G. Jackson
    . 2010. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int. Immunol. 22: 839–849.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Wiede, F.,
    2. K. Vana,
    3. L. M. Sedger,
    4. A. Lechner,
    5. H. Körner
    . 2007. TNF-dependent overexpression of CCL21 is an underlying cause of progressive lymphoaccumulation in generalized lymphoproliferative disorder. Eur. J. Immunol. 37: 351–357.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Bekiaris, V.,
    2. F. Gaspal,
    3. M.-Y. Kim,
    4. D. R. Withers,
    5. F. M. McConnell,
    6. G. Anderson,
    7. P. J. L. Lane
    . 2009. CD30 is required for CCL21 expression and CD4 T cell recruitment in the absence of lymphotoxin signals. J. Immunol. 182: 4771–4775.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Martinet, L.,
    2. T. Filleron,
    3. S. Le Guellec,
    4. P. Rochaix,
    5. I. Garrido,
    6. J.-P. Girard
    . 2013. High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β–producing dendritic cells in human breast cancer. J. Immunol. 191: 2001–2008.
    OpenUrlAbstract/FREE Full Text
  68. ↵
    1. Hindley, J. P.,
    2. E. Jones,
    3. K. Smart,
    4. H. Bridgeman,
    5. S. N. Lauder,
    6. B. Ondondo,
    7. S. Cutting,
    8. K. Ladell,
    9. K. K. Wynn,
    10. D. Withers, et al
    . 2012. T-cell trafficking facilitated by high endothelial venules is required for tumor control after regulatory T-cell depletion. Cancer Res. 72: 5473–5482.
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Drayton, D. L.,
    2. S. Liao,
    3. R. H. Mounzer,
    4. N. H. Ruddle
    . 2006. Lymphoid organ development: from ontogeny to neogenesis. Nat. Immunol. 7: 344–353.
    OpenUrlCrossRefPubMed
    1. Carragher, D. M.,
    2. J. Rangel-Moreno,
    3. T. D. Randall
    . 2008. Ectopic lymphoid tissues and local immunity. Semin. Immunol. 20: 26–42.
    OpenUrlCrossRefPubMed
  71. ↵
    1. GeurtsvanKessel, C. H.,
    2. M. A. Willart,
    3. I. M. Bergen,
    4. L. S. van Rijt,
    5. F. Muskens,
    6. D. Elewaut,
    7. A. D. Osterhaus,
    8. R. Hendriks,
    9. G. F. Rimmelzwaan,
    10. B. N. Lambrecht
    . 2009. Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. J. Exp. Med. 206: 2339–2349.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Halle, S.,
    2. H. C. Dujardin,
    3. N. Bakocevic,
    4. H. Fleige,
    5. H. Danzer,
    6. S. Willenzon,
    7. Y. Suezer,
    8. G. Hämmerling,
    9. N. Garbi,
    10. G. Sutter, et al
    . 2009. Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells. J. Exp. Med. 206: 2593–2601.
    OpenUrlAbstract/FREE Full Text
    1. Hayasaka, H.,
    2. K. Taniguchi,
    3. S. Fukai,
    4. M. Miyasaka
    . 2010. Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking. Cancer Sci. 101: 2302–2308.
    OpenUrlCrossRefPubMed
    1. van de Pavert, S. A.,
    2. R. E. Mebius
    . 2010. New insights into the development of lymphoid tissues. Nat. Rev. Immunol. 10: 664–674.
    OpenUrlCrossRefPubMed
  75. ↵
    1. Link, A.,
    2. D. L. Hardie,
    3. S. Favre,
    4. M. R. Britschgi,
    5. D. H. Adams,
    6. M. Sixt,
    7. J. G. Cyster,
    8. C. D. Buckley,
    9. S. A. Luther
    . 2011. Association of T-zone reticular networks and conduits with ectopic lymphoid tissues in mice and humans. Am. J. Pathol. 178: 1662–1675.
    OpenUrlCrossRefPubMed
    1. Huang, H.-Y.,
    2. S. A. Luther
    . 2012. Expression and function of interleukin-7 in secondary and tertiary lymphoid organs. Semin. Immunol. 24: 175–189.
    OpenUrlPubMed
  77. ↵
    1. Neyt, K.,
    2. F. Perros,
    3. C. H. GeurtsvanKessel,
    4. H. Hammad,
    5. B. N. Lambrecht
    . 2012. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 33: 297–305.
    OpenUrlCrossRefPubMed
  78. ↵
    1. Stranford, S.,
    2. N. H. Ruddle
    . 2012. Follicular dendritic cells, conduits, lymphatic vessels, and high endothelial venules in tertiary lymphoid organs: parallels with lymph node stroma. Front. Immunol. 3: 350.
    OpenUrl
  79. ↵
    1. Jones, G. W.,
    2. D. G. Hill,
    3. S. A. Jones
    . 2016. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Front. Immunol. 7: 401.
    OpenUrl
  80. ↵
    1. Legler, D. F.,
    2. M. Loetscher,
    3. R. S. Roos,
    4. I. Clark-Lewis,
    5. M. Baggiolini,
    6. B. Moser
    . 1998. B cell–attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5. J. Exp. Med. 187: 655–660.
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Ansel, K. M.,
    2. V. N. Ngo,
    3. P. L. Hyman,
    4. S. A. Luther,
    5. R. Förster,
    6. J. D. Sedgwick,
    7. J. L. Browning,
    8. M. Lipp,
    9. J. G. Cyster
    . 2000. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406: 309–314.
    OpenUrlCrossRefPubMed
    1. Luther, S. A.,
    2. H. L. Tang,
    3. P. L. Hyman,
    4. A. G. Farr,
    5. J. G. Cyster
    . 2000. Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse. Proc. Natl. Acad. Sci. USA 97: 12694–12699.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Allen, C. D. C.,
    2. K. M. Ansel,
    3. C. Low,
    4. R. Lesley,
    5. H. Tamamura,
    6. N. Fujii,
    7. J. G. Cyster
    . 2004. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat. Immunol. 5: 943–952.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Barone, F.,
    2. S. Nayar,
    3. J. Campos,
    4. T. Cloake,
    5. D. R. Withers,
    6. K.-M. Toellner,
    7. Y. Zhang,
    8. L. Fouser,
    9. B. Fisher,
    10. S. Bowman, et al
    . 2015. IL-22 regulates lymphoid chemokine production and assembly of tertiary lymphoid organs. Proc. Natl. Acad. Sci. USA 112: 11024–11029.
    OpenUrlAbstract/FREE Full Text
  85. ↵
    1. Fleige, H.,
    2. S. Ravens,
    3. G. L. Moschovakis,
    4. J. Bölter,
    5. S. Willenzon,
    6. G. Sutter,
    7. S. Häussler,
    8. U. Kalinke,
    9. I. Prinz,
    10. R. Förster
    . 2014. IL-17–induced CXCL12 recruits B cells and induces follicle formation in BALT in the absence of differentiated FDCs. J. Exp. Med. 211: 643–651.
    OpenUrlAbstract/FREE Full Text
  86. ↵
    1. Pikor, N. B.,
    2. J. L. Astarita,
    3. L. Summers-Deluca,
    4. G. Galicia,
    5. J. Qu,
    6. L. A. Ward,
    7. S. Armstrong,
    8. C. X. Dominguez,
    9. D. Malhotra,
    10. B. Heiden, et al
    . 2015. Integration of Th17- and lymphotoxin-derived signals initiates meningeal-resident stromal cell remodeling to propagate neuroinflammation. Immunity 43: 1160–1173.
    OpenUrlCrossRefPubMed
  87. ↵
    1. Rangel-Moreno, J.,
    2. J. E. Moyron-Quiroz,
    3. L. Hartson,
    4. K. Kusser,
    5. T. D. Randall
    . 2007. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl. Acad. Sci. USA 104: 10577–10582.
    OpenUrlAbstract/FREE Full Text
  88. ↵
    1. Rangel-Moreno, J.,
    2. D. M. Carragher,
    3. M. de la Luz Garcia-Hernandez,
    4. J. Y. Hwang,
    5. K. Kusser,
    6. L. Hartson,
    7. J. K. Kolls,
    8. S. A. Khader,
    9. T. D. Randall
    . 2011. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12: 639–646.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Hiraoka, N.,
    2. Y. Ino,
    3. R. Yamazaki-Itoh
    . 2016. Tertiary lymphoid organs in cancer tissues. Front. Immunol. 7: 244.
    OpenUrl
  90. ↵
    1. Sautès-Fridman, C.,
    2. M. Lawand,
    3. N. A. Giraldo,
    4. H. Kaplon,
    5. C. Germain,
    6. W. H. Fridman,
    7. M.-C. Dieu-Nosjean
    . 2016. Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention. Front. Immunol. 7: 407.
    OpenUrl
  91. ↵
    1. Dieu-Nosjean, M.-C.,
    2. M. Antoine,
    3. C. Danel,
    4. D. Heudes,
    5. M. Wislez,
    6. V. Poulot,
    7. N. Rabbe,
    8. L. Laurans,
    9. E. Tartour,
    10. L. de Chaisemartin, et al
    . 2008. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J. Clin. Oncol. 26: 4410–4417.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. de Chaisemartin, L.,
    2. J. Goc,
    3. D. Damotte,
    4. P. Validire,
    5. P. Magdeleinat,
    6. M. Alifano,
    7. I. Cremer,
    8. W.-H. Fridman,
    9. C. Sautès-Fridman,
    10. M.-C. Dieu-Nosjean
    . 2011. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 71: 6391–6399.
    OpenUrlAbstract/FREE Full Text
  93. ↵
    1. Goc, J.,
    2. C. Germain,
    3. T. K. D. Vo-Bourgais,
    4. A. Lupo,
    5. C. Klein,
    6. S. Knockaert,
    7. L. de Chaisemartin,
    8. H. Ouakrim,
    9. E. Becht,
    10. M. Alifano, et al
    . 2014. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 74: 705–715.
    OpenUrlAbstract/FREE Full Text
  94. ↵
    1. Bindea, G.,
    2. B. Mlecnik,
    3. M. Tosolini,
    4. A. Kirilovsky,
    5. M. Waldner,
    6. A. C. Obenauf,
    7. H. Angell,
    8. T. Fredriksen,
    9. L. Lafontaine,
    10. A. Berger, et al
    . 2013. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39: 782–795.
    OpenUrlCrossRefPubMed
  95. ↵
    1. Cipponi, A.,
    2. M. Mercier,
    3. T. Seremet,
    4. J.-F. Baurain,
    5. I. Théate,
    6. J. van den Oord,
    7. M. Stas,
    8. T. Boon,
    9. P. G. Coulie,
    10. N. van Baren
    . 2012. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res. 72: 3997–4007.
    OpenUrlAbstract/FREE Full Text
  96. ↵
    1. Coppola, D.,
    2. M. Nebozhyn,
    3. F. Khalil,
    4. H. Dai,
    5. T. Yeatman,
    6. A. Loboda,
    7. J. J. Mulé
    . 2011. Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling. Am. J. Pathol. 179: 37–45.
    OpenUrlCrossRefPubMed
  97. ↵
    1. Di Caro, G.,
    2. F. Bergomas,
    3. F. Grizzi,
    4. A. Doni,
    5. P. Bianchi,
    6. A. Malesci,
    7. L. Laghi,
    8. P. Allavena,
    9. A. Mantovani,
    10. F. Marchesi
    . 2014. Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin. Cancer Res. 20: 2147–2158.
    OpenUrlAbstract/FREE Full Text
  98. ↵
    1. Finkin, S.,
    2. D. Yuan,
    3. I. Stein,
    4. K. Taniguchi,
    5. A. Weber,
    6. K. Unger,
    7. J. L. Browning,
    8. N. Goossens,
    9. S. Nakagawa,
    10. G. Gunasekaran, et al
    . 2015. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol. 16: 1235–1244.
    OpenUrlCrossRefPubMed
  99. ↵
    1. Germain, C.,
    2. S. Gnjatic,
    3. F. Tamzalit,
    4. S. Knockaert,
    5. R. Remark,
    6. J. Goc,
    7. A. Lepelley,
    8. E. Becht,
    9. S. Katsahian,
    10. G. Bizouard, et al
    . 2014. Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am. J. Respir. Crit. Care Med. 189: 832–844.
    OpenUrlCrossRefPubMed
    1. Giraldo, N. A.,
    2. E. Becht,
    3. F. Pagès,
    4. G. Skliris,
    5. V. Verkarre,
    6. Y. Vano,
    7. A. Mejean,
    8. N. Saint-Aubert,
    9. L. Lacroix,
    10. I. Natario, et al
    . 2015. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin. Cancer Res. 21: 3031–3040.
    OpenUrlAbstract/FREE Full Text
    1. Goeppert, B.,
    2. L. Frauenschuh,
    3. M. Zucknick,
    4. A. Stenzinger,
    5. M. Andrulis,
    6. F. Klauschen,
    7. K. Joehrens,
    8. A. Warth,
    9. M. Renner,
    10. A. Mehrabi, et al
    . 2013. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br. J. Cancer 109: 2665–2674.
    OpenUrl
  102. ↵
    1. Gu-Trantien, C.,
    2. S. Loi,
    3. S. Garaud,
    4. C. Equeter,
    5. M. Libin,
    6. A. de Wind,
    7. M. Ravoet,
    8. H. Le Buanec,
    9. C. Sibille,
    10. G. Manfouo-Foutsop, et al
    . 2013. CD4+ follicular helper T cell infiltration predicts breast cancer survival. J. Clin. Invest. 123: 2873–2892.
    OpenUrlCrossRefPubMed
  103. ↵
    1. Hennequin, A.,
    2. V. Derangère,
    3. R. Boidot,
    4. L. Apetoh,
    5. J. Vincent,
    6. D. Orry,
    7. J. Fraisse,
    8. S. Causeret,
    9. F. Martin,
    10. L. Arnould, et al
    . 2015. Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients. OncoImmunology 5: e1054598.
    OpenUrl
    1. Hiraoka, N.,
    2. Y. Ino,
    3. R. Yamazaki-Itoh,
    4. Y. Kanai,
    5. T. Kosuge,
    6. K. Shimada
    . 2015. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. Br. J. Cancer 112: 1782–1790.
    OpenUrlPubMed
  105. ↵
    1. Lee, H. J.,
    2. I. A. Park,
    3. I. H. Song,
    4. S.-J. Shin,
    5. J. Y. Kim,
    6. J. H. Yu,
    7. G. Gong
    . 2016. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. J. Clin. Pathol. 69: 422–430.
    OpenUrlAbstract/FREE Full Text
  106. ↵
    1. Martinet, L.,
    2. I. Garrido,
    3. T. Filleron,
    4. S. Le Guellec,
    5. E. Bellard,
    6. J.-J. Fournie,
    7. P. Rochaix,
    8. J.-P. Girard
    . 2011. Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer. Cancer Res. 71: 5678–5687.
    OpenUrlAbstract/FREE Full Text
  107. ↵
    1. McMullen, T. P. W.,
    2. R. Lai,
    3. L. Dabbagh,
    4. T. M. Wallace,
    5. C. J. de Gara
    . 2010. Survival in rectal cancer is predicted by T cell infiltration of tumour-associated lymphoid nodules. Clin. Exp. Immunol. 161: 81–88.
    OpenUrlPubMed
    1. Meshcheryakova, A.,
    2. D. Tamandl,
    3. E. Bajna,
    4. J. Stift,
    5. M. Mittlboeck,
    6. M. Svoboda,
    7. D. Heiden,
    8. S. Stremitzer,
    9. E. Jensen-Jarolim,
    10. T. Grünberger, et al
    . 2014. B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer. PLoS One 9: e99008.
    OpenUrl
  109. ↵
    1. Messina, J. L.,
    2. D. A. Fenstermacher,
    3. S. Eschrich,
    4. X. Qu,
    5. A. E. Berglund,
    6. M. C. Lloyd,
    7. M. J. Schell,
    8. V. K. Sondak,
    9. J. S. Weber,
    10. J. J. Mulé
    . 2012. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci. Rep. 2: 765.
    OpenUrlCrossRefPubMed
  110. ↵
    1. Remark, R.,
    2. M. Alifano,
    3. I. Cremer,
    4. A. Lupo,
    5. M.-C. Dieu-Nosjean,
    6. M. Riquet,
    7. L. Crozet,
    8. H. Ouakrim,
    9. J. Goc,
    10. A. Cazes, et al
    . 2013. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin. Cancer Res. 19: 4079–4091.
    OpenUrlAbstract/FREE Full Text
  111. ↵
    1. Sakai, Y.,
    2. H. Hoshino,
    3. R. Kitazawa,
    4. M. Kobayashi
    . 2014. High endothelial venule-like vessels and lymphocyte recruitment in testicular seminoma. Andrology 2: 282–289.
    OpenUrl
  112. ↵
    1. Väyrynen, J. P.,
    2. S. A. Sajanti,
    3. K. Klintrup,
    4. J. Mäkelä,
    5. K.-H. Herzig,
    6. T. J. Karttunen,
    7. A. Tuomisto,
    8. M. J. Mäkinen
    . 2014. Characteristics and significance of colorectal cancer associated lymphoid reaction. Int. J. Cancer 134: 2126–2135.
    OpenUrlCrossRefPubMed
  113. ↵
    1. Wirsing, A. M.,
    2. O. G. Rikardsen,
    3. S. E. Steigen,
    4. L. Uhlin-Hansen,
    5. E. Hadler-Olsen
    . 2014. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC Clin. Pathol. 14: 38.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Bergomas, F.,
    2. F. Grizzi,
    3. A. Doni,
    4. S. Pesce,
    5. L. Laghi,
    6. P. Allavena,
    7. A. Mantovani,
    8. F. Marchesi
    . 2011. Tertiary intratumor lymphoid tissue in colo-rectal cancer. Cancers 4: 1–10.
    OpenUrl
  115. ↵
    1. Joshi, N. S.,
    2. E. H. Akama-Garren,
    3. Y. Lu,
    4. D.-Y. Lee,
    5. G. P. Chang,
    6. A. Li,
    7. M. DuPage,
    8. T. Tammela,
    9. N. R. Kerper,
    10. A. F. Farago, et al
    . 2015. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43: 579–590.
    OpenUrlCrossRefPubMed
  116. ↵
    1. Rodriguez, A. B.,
    2. J. D. Peske,
    3. V. H. Engelhard
    . Identification and characterization of tertiary lymphoid structures in murine melanoma. Methods Mol. Biol. In press.
  117. ↵
    1. Willis, S. N.,
    2. S. S. Mallozzi,
    3. S. J. Rodig,
    4. K. M. Cronk,
    5. S. L. McArdel,
    6. T. Caron,
    7. G. S. Pinkus,
    8. L. Lovato,
    9. K. L. Shampain,
    10. D. E. Anderson, et al
    . 2009. The microenvironment of germ cell tumors harbors a prominent antigen-driven humoral response. J. Immunol. 182: 3310–3317.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Bento, D. C.,
    2. E. Jones,
    3. S. Junaid,
    4. J. Tull,
    5. G. T. Williams,
    6. A. Godkin,
    7. A. Ager,
    8. A. Gallimore
    . 2015. High endothelial venules are rare in colorectal cancers but accumulate in extra-tumoral areas with disease progression. OncoImmunology 4: e974374.
    OpenUrl
  119. ↵
    1. Behr, D. S.,
    2. W. K. Peitsch,
    3. C. Hametner,
    4. F. Lasitschka,
    5. R. Houben,
    6. K. Schönhaar,
    7. J. Michel,
    8. C. Dollt,
    9. M. Goebeler,
    10. A. Marx, et al
    . 2014. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. Int. J. Clin. Exp. Pathol. 7: 7610–7621.
    OpenUrl
  120. ↵
    1. Figenschau, S. L.,
    2. S. Fismen,
    3. K. A. Fenton,
    4. C. Fenton,
    5. E. S. Mortensen
    . 2015. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients. BMC Cancer 15: 101.
    OpenUrl
  121. ↵
    1. Hsao, H.-M.,
    2. W. Li,
    3. A. E. Gelman,
    4. A. S. Krupnick,
    5. D. Kreisel
    . 2015. The role of lymphoid neogenesis in allografts. Am. J. Transplant. 16: 1079–1085.
    OpenUrl
    1. Koenig, A.,
    2. O. Thaunat
    . 2016. Lymphoid neogenesis and tertiary lymphoid organs in transplanted organs. Front. Immunol. 7: 646.
    OpenUrl
  123. ↵
    1. Li, W.,
    2. A. C. Bribriesco,
    3. R. G. Nava,
    4. A. A. Brescia,
    5. A. Ibricevic,
    6. J. H. Spahn,
    7. S. L. Brody,
    8. J. H. Ritter,
    9. A. E. Gelman,
    10. A. S. Krupnick, et al
    . 2012. Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis. Mucosal Immunol. 5: 544–554.
    OpenUrlPubMed
  124. ↵
    Bruno, T. C., P. Ebner, B. Moore, O. Squalls, K. Waugh, E. B. Eruslanov, S. Singhal, J. Mitchell, W. Franklin, D. Merrick, et al. 2017. Antigen-presenting tumor B cells impact the phenotype of CD4 tumor infiltrating T cells in lung cancer patients. J. Immunol. 198 (Suppl. 1): 130.26.
    1. Coughlin, C. M.,
    2. B. A. Vance,
    3. S. A. Grupp,
    4. R. H. Vonderheide
    . 2004. RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood 103: 2046–2054.
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Yuseff, M.-I.,
    2. P. Pierobon,
    3. A. Reversat,
    4. A.-M. Lennon-Duménil
    . 2013. How B cells capture, process and present antigens: a crucial role for cell polarity. Nat. Rev. Immunol. 13: 475–486.
    OpenUrlCrossRefPubMed
  127. ↵
    1. Germain, C.,
    2. S. Gnjatic,
    3. M.-C. Dieu-Nosjean
    . 2015. Tertiary lymphoid structure-associated B cells are key players in anti-tumor immunity. Front. Immunol. 6: 67.
    OpenUrlPubMed
  128. ↵
    1. Nelson, B. H.
    2010. CD20+ B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 185: 4977–4982.
    OpenUrlAbstract/FREE Full Text
  129. ↵
    1. Affara, N. I.,
    2. B. Ruffell,
    3. T. R. Medler,
    4. A. J. Gunderson,
    5. M. Johansson,
    6. S. Bornstein,
    7. E. Bergsland,
    8. M. Steinhoff,
    9. Y. Li,
    10. Q. Gong, et al
    . 2014. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 25: 809–821.
    OpenUrlCrossRefPubMed
    1. Schioppa, T.,
    2. R. Moore,
    3. R. G. Thompson,
    4. E. C. Rosser,
    5. H. Kulbe,
    6. S. Nedospasov,
    7. C. Mauri,
    8. L. M. Coussens,
    9. F. R. Balkwill
    . 2011. B regulatory cells and the tumor-promoting actions of TNF-α during squamous carcinogenesis. Proc. Natl. Acad. Sci. USA 108: 10662–10667.
    OpenUrlAbstract/FREE Full Text
    1. Schwartz, M.,
    2. Y. Zhang,
    3. J. D. Rosenblatt
    . 2016. B cell regulation of the anti-tumor response and role in carcinogenesis. J. Immunother. Cancer 4: 40.
    OpenUrlPubMed
  132. ↵
    1. Shah, S.,
    2. A. A. Divekar,
    3. S. P. Hilchey,
    4. H. M. Cho,
    5. C. L. Newman,
    6. S. U. Shin,
    7. H. Nechustan,
    8. P. M. Challita-Eid,
    9. B. M. Segal,
    10. K. H. Yi,
    11. J. D. Rosenblatt
    . 2005. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int. J. Cancer 117: 574–586.
    OpenUrlCrossRefPubMed
  133. ↵
    1. Sawa, S.,
    2. M. Cherrier,
    3. M. Lochner,
    4. N. Satoh-Takayama,
    5. H. J. Fehling,
    6. F. Langa,
    7. J. P. Di Santo,
    8. G. Eberl
    . 2010. Lineage relationship analysis of RORgammat+ innate lymphoid cells. Science 330: 665–669.
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Kim, D.,
    2. R. E. Mebius,
    3. J. D. MacMicking,
    4. S. Jung,
    5. T. Cupedo,
    6. Y. Castellanos,
    7. J. Rho,
    8. B. R. Wong,
    9. R. Josien,
    10. N. Kim, et al
    . 2000. Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J. Exp. Med. 192: 1467–1478.
    OpenUrlAbstract/FREE Full Text
    1. Mebius, R. E.
    2003. Organogenesis of lymphoid tissues. Nat. Rev. Immunol. 3: 292–303.
    OpenUrlCrossRefPubMed
    1. Randall, T. D.,
    2. D. M. Carragher,
    3. J. Rangel-Moreno
    . 2008. Development of secondary lymphoid organs. Annu. Rev. Immunol. 26: 627–650.
    OpenUrlCrossRefPubMed
    1. Withers, D. R.
    2011. Lymphoid tissue inducer cells. Curr. Biol. 21: R381–R382.
    OpenUrlCrossRefPubMed
    1. Lane, P. J. L.,
    2. F. M. Gaspal,
    3. F. M. McConnell,
    4. D. R. Withers,
    5. G. Anderson
    . 2012. Lymphoid tissue inducer cells: pivotal cells in the evolution of CD4 immunity and tolerance? Front. Immunol. 3: 24.
    OpenUrlCrossRefPubMed
  139. ↵
    1. Fletcher, A. L.,
    2. S. E. Acton,
    3. K. Knoblich
    . 2015. Lymph node fibroblastic reticular cells in health and disease. Nat. Rev. Immunol. 15: 350–361.
    OpenUrlCrossRefPubMed
  140. ↵
    1. Nakano, H.,
    2. M. D. Gunn
    . 2001. Gene duplications at the chemokine locus on mouse chromosome 4: multiple strain-specific haplotypes and the deletion of secondary lymphoid-organ chemokine and EBI-1 ligand chemokine genes in the plt mutation. J. Immunol. 166: 361–369.
    OpenUrlAbstract/FREE Full Text
    1. Ohl, L.,
    2. G. Henning,
    3. S. Krautwald,
    4. M. Lipp,
    5. S. Hardtke,
    6. G. Bernhardt,
    7. O. Pabst,
    8. R. Förster
    . 2003. Cooperating mechanisms of CXCR5 and CCR7 in development and organization of secondary lymphoid organs. J. Exp. Med. 197: 1199–1204.
    OpenUrlAbstract/FREE Full Text
  142. ↵
    1. Luther, S. A.,
    2. K. M. Ansel,
    3. J. G. Cyster
    . 2003. Overlapping roles of CXCL13, interleukin 7 receptor α, and CCR7 ligands in lymph node development. J. Exp. Med. 197: 1191–1198.
    OpenUrlAbstract/FREE Full Text
  143. ↵
    1. De Togni, P.,
    2. J. Goellner,
    3. N. H. Ruddle,
    4. P. R. Streeter,
    5. A. Fick,
    6. S. Mariathasan,
    7. S. C. Smith,
    8. R. Carlson,
    9. L. P. Shornick,
    10. J. Strauss-Schoenberger, et al
    . 1994. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264: 703–707.
    OpenUrlAbstract/FREE Full Text
    1. Alimzhanov, M. B.,
    2. D. V. Kuprash,
    3. M. H. Kosco-Vilbois,
    4. A. Luz,
    5. R. L. Turetskaya,
    6. A. Tarakhovsky,
    7. K. Rajewsky,
    8. S. A. Nedospasov,
    9. K. Pfeffer
    . 1997. Abnormal development of secondary lymphoid tissues in lymphotoxin β-deficient mice. Proc. Natl. Acad. Sci. USA 94: 9302–9307.
    OpenUrlAbstract/FREE Full Text
    1. Koni, P. A.,
    2. R. Sacca,
    3. P. Lawton,
    4. J. L. Browning,
    5. N. H. Ruddle,
    6. R. A. Flavell
    . 1997. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 6: 491–500.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Fütterer, A.,
    2. K. Mink,
    3. A. Luz,
    4. M. H. Kosco-Vilbois,
    5. K. Pfeffer
    . 1998. The lymphotoxin β receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 9: 59–70.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Kuprash, D. V.,
    2. M. B. Alimzhanov,
    3. A. V. Tumanov,
    4. A. O. Anderson,
    5. K. Pfeffer,
    6. S. A. Nedospasov
    . 1999. TNF and lymphotoxin β cooperate in the maintenance of secondary lymphoid tissue microarchitecture but not in the development of lymph nodes. J. Immunol. 163: 6575–6580.
    OpenUrlAbstract/FREE Full Text
  148. ↵
    1. Ngo, V. N.,
    2. H. Korner,
    3. M. D. Gunn,
    4. K. N. Schmidt,
    5. D. S. Riminton,
    6. M. D. Cooper,
    7. J. L. Browning,
    8. J. D. Sedgwick,
    9. J. G. Cyster
    . 1999. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J. Exp. Med. 189: 403–412.
    OpenUrlAbstract/FREE Full Text
  149. ↵
    1. Tumanov, A.,
    2. D. Kuprash,
    3. M. Lagarkova,
    4. S. Grivennikov,
    5. K. Abe,
    6. A. Shakhov,
    7. L. Drutskaya,
    8. C. Stewart,
    9. A. Chervonsky,
    10. S. Nedospasov
    . 2002. Distinct role of surface lymphotoxin expressed by B cells in the organization of secondary lymphoid tissues. Immunity 17: 239–250.
    OpenUrlCrossRefPubMed
  150. ↵
    1. Tumanov, A. V.,
    2. S. I. Grivennikov,
    3. A. A. Kruglov,
    4. Y. V. Shebzukhov,
    5. E. P. Koroleva,
    6. Y. Piao,
    7. C. Y. Cui,
    8. D. V. Kuprash,
    9. S. A. Nedospasov
    . 2010. Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood 116: 3456–3464.
    OpenUrlAbstract/FREE Full Text
  151. ↵
    1. Luther, S. A.,
    2. T. Lopez,
    3. W. Bai,
    4. D. Hanahan,
    5. J. G. Cyster
    . 2000. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 12: 471–481.
    OpenUrlCrossRefPubMed
  152. ↵
    1. Luther, S. A.,
    2. A. Bidgol,
    3. D. C. Hargreaves,
    4. A. Schmidt,
    5. Y. Xu,
    6. J. Paniyadi,
    7. M. Matloubian,
    8. J. G. Cyster
    . 2002. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J. Immunol. 169: 424–433.
    OpenUrlAbstract/FREE Full Text
  153. ↵
    1. Marinkovic, T.,
    2. A. Garin,
    3. Y. Yokota,
    4. Y.-X. Fu,
    5. N. H. Ruddle,
    6. G. C. Furtado,
    7. S. A. Lira
    . 2006. Interaction of mature CD3+CD4+ T cells with dendritic cells triggers the development of tertiary lymphoid structures in the thyroid. J. Clin. Invest. 116: 2622–2632.
    OpenUrlCrossRefPubMed
  154. ↵
    1. Furtado, G. C.,
    2. T. Marinkovic,
    3. A. P. Martin,
    4. A. Garin,
    5. B. Hoch,
    6. W. Hubner,
    7. B. K. Chen,
    8. E. Genden,
    9. M. Skobe,
    10. S. A. Lira
    . 2007. Lymphotoxin beta receptor signaling is required for inflammatory lymphangiogenesis in the thyroid. Proc. Natl. Acad. Sci. USA 104: 5026–5031.
    OpenUrlAbstract/FREE Full Text
    1. Gatumu, M. K.,
    2. K. Skarstein,
    3. A. Papandile,
    4. J. L. Browning,
    5. R. A. Fava,
    6. A. I. Bolstad
    . 2009. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjögren’s syndrome in salivary glands of non-obese diabetic mice. Arthritis Res. Ther. 11: R24.
    OpenUrlCrossRefPubMed
    1. Gräbner, R.,
    2. K. Lötzer,
    3. S. Döpping,
    4. M. Hildner,
    5. D. Radke,
    6. M. Beer,
    7. R. Spanbroek,
    8. B. Lippert,
    9. C. A. Reardon,
    10. G. S. Getz, et al
    . 2009. Lymphotoxin β receptor signaling promotes tertiary lymphoid organogenesis in the aorta adventitia of aged ApoE−/− mice. J. Exp. Med. 206: 233–248.
    OpenUrlAbstract/FREE Full Text
  157. ↵
    1. Motallebzadeh, R.,
    2. S. Rehakova,
    3. T. M. Conlon,
    4. T. S. Win,
    5. C. J. Callaghan,
    6. M. Goddard,
    7. E. M. Bolton,
    8. N. H. Ruddle,
    9. J. A. Bradley,
    10. G. J. Pettigrew
    . 2012. Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses. FASEB J. 26: 51–62.
    OpenUrlAbstract/FREE Full Text
  158. ↵
    1. Bénézech, C.,
    2. N.-T. Luu,
    3. J. A. Walker,
    4. A. A. Kruglov,
    5. Y. Loo,
    6. K. Nakamura,
    7. Y. Zhang,
    8. S. Nayar,
    9. L. H. Jones,
    10. A. Flores-Langarica, et al
    . 2015. Inflammation-induced formation of fat-associated lymphoid clusters. Nat. Immunol. 16: 819–828.
    OpenUrlCrossRefPubMed
    1. Furtado, G. C.,
    2. M. E. Pacer,
    3. G. Bongers,
    4. C. Bénézech,
    5. Z. He,
    6. L. Chen,
    7. M. C. Berin,
    8. G. Kollias,
    9. J. H. Caamaño,
    10. S. A. Lira
    . 2014. TNFα-dependent development of lymphoid tissue in the absence of RORγt+ lymphoid tissue inducer cells. Mucosal Immunol. 7: 602–614.
    OpenUrlCrossRefPubMed
  160. ↵
    1. Guedj, K.,
    2. J. Khallou-Laschet,
    3. M. Clement,
    4. M. Morvan,
    5. A.-T. Gaston,
    6. G. Fornasa,
    7. J. Dai,
    8. M. Gervais-Taurel,
    9. G. Eberl,
    10. J.-B. Michel, et al
    . 2014. M1 macrophages act as LTβR-independent lymphoid tissue inducer cells during atherosclerosis-related lymphoid neogenesis. Cardiovasc. Res. 101: 434–443.
    OpenUrlCrossRefPubMed
  161. ↵
    1. Peters, A.,
    2. L. A. Pitcher,
    3. J. M. Sullivan,
    4. M. Mitsdoerffer,
    5. S. E. Acton,
    6. B. Franz,
    7. K. Wucherpfennig,
    8. S. Turley,
    9. M. C. Carroll,
    10. R. A. Sobel, et al
    . 2011. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35: 986–996.
    OpenUrlCrossRefPubMed
  162. ↵
    1. Cañete, J. D.,
    2. R. Celis,
    3. N. Yeremenko,
    4. R. Sanmartí,
    5. L. van Duivenvoorde,
    6. J. Ramírez,
    7. I. Blijdorp,
    8. C. M. García-Herrero,
    9. J. L. Pablos,
    10. D. L. Baeten
    . 2015. Ectopic lymphoid neogenesis is strongly associated with activation of the IL-23 pathway in rheumatoid synovitis. Arthritis Res. Ther. 17: 173.
    OpenUrl
    1. Khader, S. A.,
    2. L. Guglani,
    3. J. Rangel-Moreno,
    4. R. Gopal,
    5. B. A. Junecko,
    6. J. J. Fountain,
    7. C. Martino,
    8. J. E. Pearl,
    9. M. Tighe,
    10. Y. Lin, et al
    . 2011. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J. Immunol. 187: 5402–5407.
    OpenUrlAbstract/FREE Full Text
  164. ↵
    1. Goya, S.,
    2. H. Matsuoka,
    3. M. Mori,
    4. H. Morishita,
    5. H. Kida,
    6. Y. Kobashi,
    7. T. Kato,
    8. Y. Taguchi,
    9. T. Osaki,
    10. I. Tachibana, et al
    . 2003. Sustained interleukin-6 signalling leads to the development of lymphoid organ-like structures in the lung. J. Pathol. 200: 82–87.
    OpenUrlCrossRefPubMed
  165. ↵
    1. Hsu, H.-C.,
    2. P. Yang,
    3. J. Wang,
    4. Q. Wu,
    5. R. Myers,
    6. J. Chen,
    7. J. Yi,
    8. T. Guentert,
    9. A. Tousson,
    10. A. L. Stanus, et al
    . 2008. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9: 166–175.
    OpenUrlCrossRefPubMed
  166. ↵
    1. Gopal, R.,
    2. J. Rangel-Moreno,
    3. S. Slight,
    4. Y. Lin,
    5. H. F. Nawar,
    6. B. A. Fallert Junecko,
    7. T. A. Reinhart,
    8. J. Kolls,
    9. T. D. Randall,
    10. T. D. Connell,
    11. S. A. Khader
    . 2013. Interleukin-17–dependent CXCL13 mediates mucosal vaccine-induced immunity against tuberculosis. Mucosal Immunol. 6: 972–984.
    OpenUrlCrossRefPubMed
  167. ↵
    1. Muniz, L. R.,
    2. M. E. Pacer,
    3. S. A. Lira,
    4. G. C. Furtado
    . 2011. A critical role for dendritic cells in the formation of lymphatic vessels within tertiary lymphoid structures. J. Immunol. 187: 828–834.
    OpenUrlAbstract/FREE Full Text
  168. ↵
    1. McDonald, K. G.,
    2. J. S. McDonough,
    3. R. D. Newberry
    . 2005. Adaptive immune responses are dispensable for isolated lymphoid follicle formation: antigen-naive, lymphotoxin-sufficient B lymphocytes drive the formation of mature isolated lymphoid follicles. J. Immunol. 174: 5720–5728.
    OpenUrlAbstract/FREE Full Text
  169. ↵
    1. Kim, H.-J.,
    2. T. Kammertoens,
    3. M. Janke,
    4. O. Schmetzer,
    5. Z. Qin,
    6. C. Berek,
    7. T. Blankenstein
    . 2004. Establishment of early lymphoid organ infrastructure in transplanted tumors mediated by local production of lymphotoxin α and in the combined absence of functional B and T cells. J. Immunol. 172: 4037–4047.
    OpenUrlAbstract/FREE Full Text
  170. ↵
    1. Mackay, F.,
    2. P. Schneider,
    3. P. Rennert,
    4. J. Browning
    . 2003. BAFF AND APRIL: a tutorial on B cell survival. Annu. Rev. Immunol. 21: 231–264.
    OpenUrlCrossRefPubMed
    1. Schiemann, B.,
    2. J. L. Gommerman,
    3. K. Vora,
    4. T. G. Cachero,
    5. S. Shulga-Morskaya,
    6. M. Dobles,
    7. E. Frew,
    8. M. L. Scott
    . 2001. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 293: 2111–2114.
    OpenUrlAbstract/FREE Full Text
  172. ↵
    1. Varfolomeev, E.,
    2. F. Kischkel,
    3. F. Martin,
    4. D. Seshasayee,
    5. H. Wang,
    6. D. Lawrence,
    7. C. Olsson,
    8. L. Tom,
    9. S. Erickson,
    10. D. French, et al
    . 2004. APRIL-deficient mice have normal immune system development. Mol. Cell. Biol. 24: 997–1006.
    OpenUrlAbstract/FREE Full Text
  173. ↵
    1. Kalled, S. L.
    2006. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin. Immunol. 18: 290–296.
    OpenUrlCrossRefPubMed
  174. ↵
    1. Vora, K. A.,
    2. L. C. Wang,
    3. S. P. Rao,
    4. Z.-Y. Liu,
    5. G. R. Majeau,
    6. A. H. Cutler,
    7. P. S. Hochman,
    8. M. L. Scott,
    9. S. L. Kalled
    . 2003. Cutting edge: germinal centers formed in the absence of B cell-activating factor belonging to the TNF family exhibit impaired maturation and function. J. Immunol. 171: 547–551.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section